Back to top
more

Becton, Dickinson and Company (BDX)

(Real Time Quote from BATS)

$240.19 USD

240.19
342,895

+2.35 (0.99%)

Updated Jul 30, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (203 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

Here's Why You Should Retain NextGen (NXGN) Stock for Now

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Buy Boston Scientific (BSX) Stock

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) owing to impressive growth in MedSurg market share.

Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.

Catalent (CTLT) Declines on Profit Warnings and CFO Exit

by Zacks Equity Research

Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.

Here's Why You Should Invest in Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), led by the strong potential in the company's dental technology joint venture, Henry Schein One.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Zacks.com featured highlights include Becton, Dickinson, Raytheon Technologies and Palantir Technologies

by Zacks Equity Research

Becton, Dickinson, Raytheon Technologies and Palantir Technologies are part of the Zacks Screen of the Week article.

BDX vs. WST: Which Stock Is the Better Value Option?

by Zacks Equity Research

BDX vs. WST: Which Stock Is the Better Value Option?

Merit Medical (MMSI) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.

Tirthankar Chakraborty headshot

3 Stocks Worth a Buy for Solid Earnings Acceleration

by Tirthankar Chakraborty

Invest in stocks like Becton, Dickinson and Company (BDX), Raytheon Technologies (RTX) & Palantir Technologies (PLTR) as of now for superb earnings acceleration.

Masimo (MASI) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Masimo's (MASI) slew of product launches.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

BD's (BDX) New Launch to Result in Optimal IV Placement

by Zacks Equity Research

BD's (BDX) latest launch is expected to advance its vision of a One-Stick Hospital Stay by improving the first-stick success in IV placements.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Catalent's (CTLT) product and service launches, and a slew of strategic deals raise optimism about the stock.

Is Avanos Medical (AVNS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Avanos Medical (AVNS) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the company.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Investors continue to feel optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is concerning.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD), owing to its broad product spectrum.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

PacBio (PACB) New Revio Workflows to Boost Agricultural Output

by Zacks Equity Research

PacBio (PACB), in collaboration with Corteva Agriscience, is likely to enable groundbreaking plant and microbial long-read sequencing workflow on Revio system.

BDX or WST: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BDX vs. WST: Which Stock Is the Better Value Option?

Reasons to Add The Cooper Companies (COO) to Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.